Please fill out the registration form to watch the On-demand Webinar Building a successful ICH Stability CoE: Collaborating at scale or to read the Syngene-Baxter case Study.

Syngene reserves the right, at its discretion, to change, modify, add, or remove participation.

Key take-aways from the Webinar:

  • Important parameters to be considered while selecting a partner for ICH Stability studies

  • Why an integrated CMC model is better than a standalone model

  • Lessons from a decade-long Stability CoE collaboration: The Syngene-Baxter R&D Centre

  • How Syngene is ensuring business continuity for its clients during these times of a global pandemic

© Syngene International Ltd.
Syngene International Ltd. Biocon Park, SEZ, Bommasandra Industrial Area - Phase - IV, Bangalore 560099 India

Host: Ashu Tandon | Chief Commercial Officer, Syngene

Ashu has 20 years experience in the global biopharmaceuticals industry which includes Sales and Account Management leadership across consulting, and outsourcing services in Research & Development. He has a successful track record of building multi-million dollar deals across multiple industry verticals and geographies.

As a member of Syngene's Executive Committee, he plays an important role in driving strategy related to Commercial activities. Prior to joining Syngene, Ashu was with IQVIA (formerly QuintilesIMS), Infosys and Accenture.

Panelist: Chetan Tamhankar | VP & Head - Clinical Development & Stability Services, Syngene

Chetan holds a Ph.D in Bio-pharmaceuticals and a Masters in Pharmacology from Mumbai University. He has more than 19 years of experience in life-sciences business spanning across CRO and healthcare sectors. He has played an active role in healthcare startups and held senior management roles in other leading CROs.

Prior to joining Syngene in 2016, Chetan was associated with SIRO Clinpharm.

Panelist: Dr. Shreekant Karmarkar | President, DAT Pharma Consulting

Dr. Shreekant Karmarkar has around 30 years of academic and industrial experience in analytical chemistry. He has developed analytical instruments and methodologies to solve industrial challenges. He has also led analytical development for Baxter’s pharmaceutical drug products right from feasibility studies, validations, transfers, regulatory submission and commercial launch, to complete life cycle management of the drug product.

Dr. Shreekant successfully led Baxter's strategic partnership with Syngene consisting of around 200 FTEs working on product sustenance and analytical work for new drug products. The collaboration turned out to be one of the best collaborations within Baxter through implementation of several key strategies. The strategies ranged from simplifying the complex, building trust, empowerment, engagement, governance and continuous improvement to Key Performance Indicators (KPIs).